10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

NR2C2

Purified Mouse Monoclonal Antibody (Mab)
Catalog # AM8731b

Product Information

Application	WB, E
Primary Accession	P49116
Reactivity	Human, Rat, Mouse
Host	Mouse
Clonality	monoclonal
Isotype	IgG2b,κ
Clone Names	2145CT343.252.77
Calculated MW	65414

Additional Information

Gene ID	7182
Other Names	Nuclear receptor subfamily 2 group C member 2, Orphan nuclear receptor TAK1, Orphan nuclear receptor TR4, Testicular receptor 4, NR2C2, TAK1, TR4
Target/Specificity	This antibody is generated from a mouse immunized with a KLH conjugated synthetic peptide between amino acids from human.
Dilution	WB~~1:1000 E~~Use at an assay dependent concentration.
Format	Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, followed by dialysis against PBS.
Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	NR2C2 is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	NR2C2
Synonyms	TAK1, TR4
Function	Orphan nuclear receptor that can act as a repressor or activator of transcription. An important repressor of nuclear receptor signaling pathways such as retinoic acid receptor, retinoid X, vitamin D3 receptor, thyroid hormone receptor and estrogen receptor pathways. May regulate gene

expression during the late phase of spermatogenesis. Together with NR2C1, forms the core of the DRED (direct repeat erythroid-definitive) complex that represses embryonic and fetal globin transcription including that of GATA1. Binds to hormone response elements (HREs) consisting of two 5'-AGGTCA-3' half site direct repeat consensus sequences. Plays a fundamental role in early embryonic development and embryonic stem cells. Required for normal spermatogenesis and cerebellum development. Appears to be important for neurodevelopmentally regulated behavior (By similarity). Activates transcriptional activity of LHCG. Antagonist of PPARA-mediated transactivation.

Cellular Location Nucleus {ECO:0000255|PROSITE-ProRule:PRU00407, ECO:0000269|PubMed:10644740, ECO:0000269|PubMed:15302918}


Background

Orphan nuclear receptor that can act as a repressor or activator of transcription. An important repressor of nuclear receptor signaling pathways such as retinoic acid receptor, retinoid X, vitamin D3 receptor, thyroid hormone receptor and estrogen receptor pathways. May regulate gene expression during the late phase of spermatogenesis. Together with NR2C1, forms the core of the DRED (direct repeat erythroid-definitive) complex that represses embryonic and fetal globin transcription including that of GATA1. Binds to hormone response elements (HREs) consisting of two 5'-AGGTCA-3' half site direct repeat consensus sequences. Plays a fundamental role in early embryonic development and embryonic stem cells. Required for normal spermatogenesis and cerebellum development. Appears to be important for neurodevelopmentally regulated behavior (By similarity). Activates transcriptional activity of LHCG. Antagonist of PPARA-mediated transactivation.

References

Hirose T.,et al.Mol. Endocrinol. 8:1667-1680(1994).
Chang C.,et al.Proc. Natl. Acad. Sci. U.S.A. 91:6040-6044(1994).
Kobayashi T.,et al.FEBS Lett. 582:2737-2744(2008).
Ota T.,et al.Nat. Genet. 36:40-45(2004).
Muzny D.M.,et al.Nature 440:1194-1198(2006).

Images



All lanes : Anti-NR2C2 Antibody at 1:1000 dilution Lane 1: PC-3 whole cell lysate Lane 2: Jurkat whole cell lysate Lane 3: MoLT-4 whole cell lysate Lane 4: F9 whole cell lysate Lane 5: NIH/3T3 whole cell lysate Lane 6: PC-12 whole cell lysate Lane 7: CHO whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Mouse IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 70 kDa Blocking/Dilution buffer: 5% NFDM/TBST.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.